← Back to Search

Anti-metabolites

ADX-2191 (intravitreal methotrexate 0.8%) for Proliferative Vitreoretinopathy

Phase 3
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up efficacy assessment period (week 1 to week 24)
Awards & highlights

Study Summary

This trial is testing a new drug to see if it can help prevent a serious eye condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~efficacy assessment period (week 1 to week 24)
This trial's timeline: 3 weeks for screening, Varies for treatment, and efficacy assessment period (week 1 to week 24) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrent retinal detachment
Secondary outcome measures
Best-corrected visual acuity (BCVA) change from baseline

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ADX-2191 (intravitreal methotrexate 0.8%)Experimental Treatment1 Intervention
ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.
Group II: Standard surgical care procedureActive Control1 Intervention
Standard procedure performed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADX-2191 (intravitreal methotrexate 0.8%)
2019
Completed Phase 3
~110

Find a Location

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor
29 Previous Clinical Trials
3,922 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
2019. "The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04136366.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top